AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 ...

Retrieved on: 2024-04-29 15:55:02

Tags for this article:

Orphan drugs

Rintatolimod

Private Securities Litigation Reform Act

PD-L1

Forward-looking statement

AIM ImmunoTech Inc.

Ampligen

Click the tags to see associated articles and topics

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 .... View article details on hiswai:

Excerpt

Hemispherx Biopharma-stock · News for Hemispherx Biopharma · AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study ...

Article found on: markets.businessinsider.com

View Original Article